Protocol Ledger

NCT04919811 · Phase II · ACTIVE NOT RECRUITING

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

Interventional Phase II clinical trial protocol NCT04919811 sponsored by Nuvation Bio in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-01 Enrollment: 217 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04919811
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)217 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04919811
Protocol FieldVerified Registry Value
NCT IdentifierNCT04919811
Consolidated Lead SponsorNuvation Bio
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment217 participants (ACTUAL)
Registered Start Date2021-09-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI